Phase I, Dose Escalation Study of Decitabine | Aplastic Anemia & MDS International Foundation
Phase I, Dose Escalation Study of Decitabine

Clinical Trial: NCT02264873

For more details on this clinical trial, including contact information, please see this trial’s listing on

Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML). This study is based on the hypothesis that Decitabine delivered after allo-hematopoietic stem cell transplant (HSCT) in patients with leukemia will enhance disease control by the allogeneic immune system and lead to a longer disease free survival. The study is designed to provide safety data of low-dosing in the post-transplant setting.

Study Date: 
Wed, 10/01/2014 to Sat, 10/01/2016
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Drug: Decitabine Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days. Other Name: Decitabine, Dacogen